• October 23, 2019

    Bulgaria’s Young Talents in The Field of Synthetic Biology Expressed Their Gratitude for The Support Provided


    Tchaikapharma High Quality Medicines Ltd. supports Bulgaria’s Team of Synthetic Biology young specialists at their participation in the biggest bio engineering contest on the Planet – iGEM. The competition takes place in Boston, USA each year and accommodates more than 350 university teams from around the world. The Bulgarian team consists of future scientists and doctors from the Sofia University “Saint Kliment Ohridski”.

    Besides being a platform for young scientist development, iGEM is also looking to obtain solutions to socially viable challenges. The Bulgarian project is dedicated to a global issue – resistance of pathogenic microbes to antibiotics. Antimicrobial resistance is one of the main threats to human and animal health. It causes more than 33 000 deaths in the European Union each year and financial losses are over 1.5 billion Euro.

    The negative tendency for constant growth of the number of infections such as tuberculosis, pneumonia and others, which are caused by pathogenic microbes that are resistant to the currently applied medicines, define the antimicrobial resistance as a global issue with a significant relevance. According to the World Health Association and the European Commission, if no new treatments are found up to 2050, 10 million people will die every year due to infections, caused by multi-resistant bacteria.

    The team will travel at the end of the month and is currently preparing for the competition at the Sofia Tech Park labs.


  • Tchaikapharma High Quality Medicines ranks among the leaders in the Prescription Drugs (Rx) market for the past 12 months (as of June 2019).


    The ranking “Top 10 Corporations in the market for prescription products” of the world’s leading analytics company IQVIA  takes into account sales at end-customer prices, with Tchaikapharma increasing its market share is now ranked second by number of packages sold.


    The top ten Rx companies in Bulgaria hold 45% of the total market for prescription drugs.

  • September 18, 2018

    By the end of 2018, Tchaikapharma expects to be issued with Marketing Authorizations for three new prescription drugs, which will enrich the portfolio and the well-developed therapeutic baskets of the company with the following medications and indications:


    Chlorthidon (chlorthalidone) – for the treatment of arterial hypertension, essential or renovascular, or isolated systolic hypertension.


    PlaquEx Combi (clopidogrel/acetylsalicylic acid) – for the secondary prevention of acute cardiovascular events.


    Methylprednisolone-Tchaikapharma (methylprednisolone) – for the treatment of endocrine, rheumatic, collagenosis and immune-complex, skin, eye, gastrointestinal, respiratory,  hematological, oncology and edema diseases, as well as allergic conditions.


    Tchaikapharma International Press Center

  • September 12, 2018

    Tchaikapharma completed the bioequivalence clinical trials of 4 new dual-component pharmaceutical products for the treatment of arterial hypertension and other cardiovascular diseases – with sucsess. The new drug fixed-dosage combinations with angiotensin receptor blockers and thiazide or thiazide-similar diuretics represent innovative solutions for an advanced medical care.


    The researched and other already registered new combined pharmaceutical products are innovative scientific solutions developed by Tchaikapharma and are extensively prescribed by doctors and are met with a wide satisfaction by patients – in Bulgaria and a number of pharmaceutical markets in the EU.


    On 20 August 2018, the Food and Drug Administration of the USA made a proposal for simplification of the registration procedure for exactly this kind of pharmaceutical combinations and the Administration described them as “complex” and accepted their innovative combined effect and high efficacy, which cannot be found in the already known mono-component generic medications.


    Tchaikapharma’s laboratories are completing the development, and more importantly, are about to finish – within the next 18 months – the clinical trials of the three-component pharmaceutical products for the treatment of cardiovascular disease and diabetes.


    Cardiovascular diseases and diabetes are the chronicle conditions with the highest morbidity and longest duration in the EU countries, which lead to acute complications such as myocardial infarction, stroke and other severe life-threatening events.


    Tchaikapharma International Press Center

  • May 3, 2018

    Pizona Combi contains pioglitazone and metformin that controls blood sugar levels.
    It helps the body to utilize better produced by body insulin when metformin alone is insufficient.
    The medicinal product is subject to medical prescription.
    For more details, please check section Products
    ATC код: A10B 02